PortalPublikationenPredictors of recurrence of atrial fibrillation within the f...

Predictors of recurrence of atrial fibrillation within the first 3 months after ablation

Standard

Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. / Zink, Matthias Daniel; Chua, Winnie; Zeemering, Stef; di Biase, Luigi; Antoni, Bayes de Luna; David, Callans; Hindricks, Gerhard; Haeusler, Karl Georg; Al-Khalidi, Hussein R; Piccini, Jonathan P; Mont, Lluís; Nielsen, Jens Cosedis; Escobar, Luis Alberto; de Bono, Joseph; Van Gelder, Isabelle C; de Potter, Tom; Scherr, Daniel; Themistoclakis, Sakis; Todd, Derick; Kirchhof, Paulus; Schotten, Ulrich.

in: EUROPACE, Jahrgang 22, Nr. 9, 01.09.2020, S. 1337-1344.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Zink, MD, Chua, W, Zeemering, S, di Biase, L, Antoni, BDL, David, C, Hindricks, G, Haeusler, KG, Al-Khalidi, HR, Piccini, JP, Mont, L, Nielsen, JC, Escobar, LA, de Bono, J, Van Gelder, IC, de Potter, T, Scherr, D, Themistoclakis, S, Todd, D, Kirchhof, P & Schotten, U 2020, 'Predictors of recurrence of atrial fibrillation within the first 3 months after ablation', EUROPACE, Jg. 22, Nr. 9, S. 1337-1344. https://doi.org/10.1093/europace/euaa132

APA

Zink, M. D., Chua, W., Zeemering, S., di Biase, L., Antoni, B. D. L., David, C., Hindricks, G., Haeusler, K. G., Al-Khalidi, H. R., Piccini, J. P., Mont, L., Nielsen, J. C., Escobar, L. A., de Bono, J., Van Gelder, I. C., de Potter, T., Scherr, D., Themistoclakis, S., Todd, D., ... Schotten, U. (2020). Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. EUROPACE, 22(9), 1337-1344. https://doi.org/10.1093/europace/euaa132

Vancouver

Zink MD, Chua W, Zeemering S, di Biase L, Antoni BDL, David C et al. Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. EUROPACE. 2020 Sep 1;22(9):1337-1344. https://doi.org/10.1093/europace/euaa132

Bibtex

@article{9fa5b2ed64ed4622976adfae3e42e21a,
title = "Predictors of recurrence of atrial fibrillation within the first 3 months after ablation",
abstract = "AIMS: Freedom from atrial fibrillation (AF) at 1 year can be achieved in 50-70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated with later recurrent AF. The aim of this investigation is to identify clinical and procedural factors associated with recurrence of AF early after ablation.METHODS AND RESULTS: We retrospectively analysed data for recurrence of AF within the first 3 months after catheter ablation from the randomized controlled AXAFA-AFNET 5 trial, which demonstrated that continuous anticoagulation with apixaban is as safe and as effective compared to vitamin K antagonists in 678 patients undergoing first AF ablation. The primary outcome of first recurrent AF within 90 days was observed in 163 (28%) patients, in which 78 (48%) patients experienced an event within the first 14 days post-ablation. After multivariable adjustment, a history of stroke/transient ischaemic attack [hazard ratio (HR) 1.54, 95% confidence interval (CI) 0.93-2.6; P = 0.11], coronary artery disease (HR 1.85, 95% CI 1.20-2.86; P = 0.005), cardioversion during ablation (HR 1.78, 95% CI 1.26-2.49; P = 0.001), and an age:sex interaction for older women (HR 1.01, 95% CI 1.00-1.01; P = 0.04) were associated with recurrent AF. The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ms vs. 122 ± 22 ms in patients without AF, P = 0.03).CONCLUSION: Half of all early AF recurrences within the first 3 months post-ablation occurred within the first 14 days post-ablation. Vascular disease and cardioversion during the procedure are strong predictors of recurrent AF. P-wave duration at follow-up was longer in patients with recurrent AF.TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02227550.",
keywords = "Aged, Atrial Fibrillation/diagnosis, Catheter Ablation/adverse effects, Female, Humans, Recurrence, Retrospective Studies, Risk Factors, Treatment Outcome",
author = "Zink, {Matthias Daniel} and Winnie Chua and Stef Zeemering and {di Biase}, Luigi and Antoni, {Bayes de Luna} and Callans David and Gerhard Hindricks and Haeusler, {Karl Georg} and Al-Khalidi, {Hussein R} and Piccini, {Jonathan P} and Llu{\'i}s Mont and Nielsen, {Jens Cosedis} and Escobar, {Luis Alberto} and {de Bono}, Joseph and {Van Gelder}, {Isabelle C} and {de Potter}, Tom and Daniel Scherr and Sakis Themistoclakis and Derick Todd and Paulus Kirchhof and Ulrich Schotten",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2020",
month = sep,
day = "1",
doi = "10.1093/europace/euaa132",
language = "English",
volume = "22",
pages = "1337--1344",
journal = "EUROPACE",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Predictors of recurrence of atrial fibrillation within the first 3 months after ablation

AU - Zink, Matthias Daniel

AU - Chua, Winnie

AU - Zeemering, Stef

AU - di Biase, Luigi

AU - Antoni, Bayes de Luna

AU - David, Callans

AU - Hindricks, Gerhard

AU - Haeusler, Karl Georg

AU - Al-Khalidi, Hussein R

AU - Piccini, Jonathan P

AU - Mont, Lluís

AU - Nielsen, Jens Cosedis

AU - Escobar, Luis Alberto

AU - de Bono, Joseph

AU - Van Gelder, Isabelle C

AU - de Potter, Tom

AU - Scherr, Daniel

AU - Themistoclakis, Sakis

AU - Todd, Derick

AU - Kirchhof, Paulus

AU - Schotten, Ulrich

N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - AIMS: Freedom from atrial fibrillation (AF) at 1 year can be achieved in 50-70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated with later recurrent AF. The aim of this investigation is to identify clinical and procedural factors associated with recurrence of AF early after ablation.METHODS AND RESULTS: We retrospectively analysed data for recurrence of AF within the first 3 months after catheter ablation from the randomized controlled AXAFA-AFNET 5 trial, which demonstrated that continuous anticoagulation with apixaban is as safe and as effective compared to vitamin K antagonists in 678 patients undergoing first AF ablation. The primary outcome of first recurrent AF within 90 days was observed in 163 (28%) patients, in which 78 (48%) patients experienced an event within the first 14 days post-ablation. After multivariable adjustment, a history of stroke/transient ischaemic attack [hazard ratio (HR) 1.54, 95% confidence interval (CI) 0.93-2.6; P = 0.11], coronary artery disease (HR 1.85, 95% CI 1.20-2.86; P = 0.005), cardioversion during ablation (HR 1.78, 95% CI 1.26-2.49; P = 0.001), and an age:sex interaction for older women (HR 1.01, 95% CI 1.00-1.01; P = 0.04) were associated with recurrent AF. The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ms vs. 122 ± 22 ms in patients without AF, P = 0.03).CONCLUSION: Half of all early AF recurrences within the first 3 months post-ablation occurred within the first 14 days post-ablation. Vascular disease and cardioversion during the procedure are strong predictors of recurrent AF. P-wave duration at follow-up was longer in patients with recurrent AF.TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02227550.

AB - AIMS: Freedom from atrial fibrillation (AF) at 1 year can be achieved in 50-70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated with later recurrent AF. The aim of this investigation is to identify clinical and procedural factors associated with recurrence of AF early after ablation.METHODS AND RESULTS: We retrospectively analysed data for recurrence of AF within the first 3 months after catheter ablation from the randomized controlled AXAFA-AFNET 5 trial, which demonstrated that continuous anticoagulation with apixaban is as safe and as effective compared to vitamin K antagonists in 678 patients undergoing first AF ablation. The primary outcome of first recurrent AF within 90 days was observed in 163 (28%) patients, in which 78 (48%) patients experienced an event within the first 14 days post-ablation. After multivariable adjustment, a history of stroke/transient ischaemic attack [hazard ratio (HR) 1.54, 95% confidence interval (CI) 0.93-2.6; P = 0.11], coronary artery disease (HR 1.85, 95% CI 1.20-2.86; P = 0.005), cardioversion during ablation (HR 1.78, 95% CI 1.26-2.49; P = 0.001), and an age:sex interaction for older women (HR 1.01, 95% CI 1.00-1.01; P = 0.04) were associated with recurrent AF. The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ms vs. 122 ± 22 ms in patients without AF, P = 0.03).CONCLUSION: Half of all early AF recurrences within the first 3 months post-ablation occurred within the first 14 days post-ablation. Vascular disease and cardioversion during the procedure are strong predictors of recurrent AF. P-wave duration at follow-up was longer in patients with recurrent AF.TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02227550.

KW - Aged

KW - Atrial Fibrillation/diagnosis

KW - Catheter Ablation/adverse effects

KW - Female

KW - Humans

KW - Recurrence

KW - Retrospective Studies

KW - Risk Factors

KW - Treatment Outcome

U2 - 10.1093/europace/euaa132

DO - 10.1093/europace/euaa132

M3 - SCORING: Journal article

C2 - 32725107

VL - 22

SP - 1337

EP - 1344

JO - EUROPACE

JF - EUROPACE

SN - 1099-5129

IS - 9

ER -